• About Adcendo
    • The Story
    • Leadership team
    • Board of Directors
    • Senior Scientific Founders
    • Clinical and Scientific Advisory Board
  • Our science
    • What are ADCs
    • The uPARAP receptor
    • Key publications
  • Investors
    • Corporate presentation
    • Press releases
    • Our investors
  • Careers
    • Open Positions
    • Company values
  • Contact

The Collagen Receptor uPARAP in Malignant Mesothelioma: A Potential Diagnostic Marker and Therapeutic Target (2021)

Oct 23, 2021

Recent Posts

  • Adcendo ApS Announces Option License Agreement with Duality Biologics to Enhance Optionality to Further Expand First-in-class ADC Pipeline
  • Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting
  • Adcendo ApS Announces Extension of Series A financing to 82M EUR to Ensure Broad Development of its First-in-class ADC Pipeline
  • Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
  • GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate

Recent Comments

No comments to show.

Adcendo ApS

For all inquiries, please contact adcendo via the e-mail address info@adcendo.com



Privacy Policy
© Adcendo ApS, All rights reserved 2022